New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
08:29 EDTVVUSVIVUS: Study finds weight loss with Qsymia improves cardiovascular risk factors
VIVUS announced the publication of a study concluding that weight loss resulting from treatment with Qsymia capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions. The improvements were significantly greater among patients who lost 10% or more of their starting weight, the company said. The study was published online in The American Journal of Cardiology.
News For VVUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
06:30 EDTVVUSVIVUS price target lowered to $2.30 from $3 at WallachBeth
WallachBeth analyst Bob Ai lowered his price target for VIVUS for $2.30 after the company announced plans to cut its sales force by one-half, to 50, in order to achieve its new corporate goal of operating cash flow being neutral or positive by the end of 2016. This is not the best move for long-term shareholders, Ai tells investors in a research note. The sales force reduction may result in a significant sales decline, the analyst believes. He keeps a Hold rating on VIVUS.
July 30, 2015
19:08 EDTVVUSVIVUS announces restructuring plan, will reduce headcount
Subscribe for More Information
16:02 EDTVVUSVIVUS reports Q2 EPS (19c), consensus (24c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use